Dr Hal Barron adds 74 GSK (NYSE: GSK) ADS through 401(k) dividends
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
GSK plc disclosed that Non-Executive Director Dr Hal Barron acquired 74 American Depositary Shares at $49.6700 each through dividend reinvestment in his GSK 401(k) plan. The transaction took place on May 15, 2026 on the New York Stock Exchange.
Positive
- None.
Negative
- None.
Key Figures
ADS acquired: 74 ADS
Purchase price per ADS: $49.6700 per ADS
Transaction date: 2026-05-15
3 metrics
ADS acquired
74 ADS
Dr Hal Barron acquisition via dividend reinvestment
Purchase price per ADS
$49.6700 per ADS
Dividend reinvestment in GSK 401(k) plan
Transaction date
2026-05-15
Acquisition of 74 ADS on NYSE
Key Terms
American Depositary Shares, PDMR, 401(k) plan, LEI
4 terms
PDMR regulatory
"Details of PDMR/person closely associated with them ('PCA')"
A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.
401(k) plan financial
"Acquisition of ADS within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends"
A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.
LEI regulatory
"Name | GSK plc b) | LEI | 5493000HZTVUYLO1D793"
A Legal Entity Identifier (LEI) is a unique 20-character code assigned to a company or organization that participates in financial markets, like a corporate passport number. It helps investors and regulators unambiguously identify counterparties across databases and transactions, reducing confusion much like using a vehicle identification number to track a car’s history; clearer identification improves transparency, risk monitoring, and regulatory reporting.
FAQ
How many GSK (GSK) ADS did Dr Hal Barron acquire and at what price?
Dr Hal Barron acquired 74 GSK American Depositary Shares at a price of $49.6700 per ADS. This was a single transaction resulting from dividend reinvestment within his GSK 401(k) plan account, executed on the New York Stock Exchange.
What was the method of Dr Hal Barron’s GSK (GSK) ADS acquisition?
The acquisition occurred via reinvestment of dividends within Dr Hal Barron’s GSK 401(k) plan account. Instead of receiving cash dividends, those funds were used to purchase 74 American Depositary Shares at $49.6700 each on the New York Stock Exchange.
On what date and exchange did the GSK (GSK) insider transaction occur?
The insider transaction took place on May 15, 2026, on the New York Stock Exchange (XNYS). On that date, 74 GSK American Depositary Shares were acquired at $49.6700 each through dividend reinvestment in Dr Hal Barron’s GSK 401(k) plan account.
Who is the GSK (GSK) insider involved in this Form 6-K transaction?
The insider is Dr Hal Barron, a Non-Executive Director of GSK plc. The filing records his acquisition of 74 American Depositary Shares at $49.6700 each through dividend reinvestment in his GSK 401(k) plan on May 15, 2026, on the New York Stock Exchange.